Skip to content

Ziva D. Cooper

6 papers in the library · 9 citations · publishing 2010-2026

Papers

Sort Most recent Most cited

Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendations.

Journal of psychopharmacology (Oxford, England) 2026 Jack E Henningfield, Sandra D Comer, Matthew L Banks et al. 5 citations

Abuse potential assessment of drugs with central nervous system activity is a critical component of the development of new medications for regulatory filings for approval worldwide. These new drug applications typically include recommendations for scheduling status as a controlled substance, if scheduling is warranted. This commentary focuses on the approach and current issues related to...

Assessing evidence supporting cannabis harm reduction practices for adolescents at clinical high-risk for psychosis: a review and clinical implementation tool.

Psychological Medicine 2024 Simon Kapler, Laura Adery, Gil D Hoftman et al.

Cannabis use is consistently associated with both increased incidence of frank psychotic disorders and acute exacerbations of psychotic symptoms in healthy individuals and people with psychosis spectrum disorders. Although there is uncertainty around causality, cannabis use may be one of a few modifiable risk factors for conversion to psychotic disorders in individuals with Clinical High Risk...

Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development

Psychedelic Medicine September 6, 2023 Marc J. Weintraub, Jessica K Jeffrey, Charles S. Grob et al. 4 citations

The trial will provide preliminary data on the feasibility, safety, acceptability, and psychosocial effects of PA-CBT. Results will inform randomized clinical trials to test the effects of PA-CBT for patients with depression and other mental health conditions, as well as hypotheses concerning mediating mechanisms at the cognitive and affective levels. ClinicalTrials.gov ID: NCT05227612.

Value Signals Guiding Choices for Cannabis Versus Non-Drug Rewards in Regular Cannabis Users

March 15, 2023 Will Lawn, Xuejun Hao, Anna B. Konova et al. preprint

Background: Despite the critical role of choice processes in substance use disorders, the neurobehavioral mechanisms guiding human decisions about drugs remain poorly understood. We adapted a neuroeconomic framework to characterize the neural encoding of subjective value (SV) for cannabis versus non-drug rewards (snacks) in near-daily cannabis users. We also assessed the impact of cannabis and...

Opioid antagonism enhances marijuana's effects in heavy marijuana smokers.

Psychopharmacology August 2010 Ziva D Cooper, Margaret Haney

Studies in laboratory animals strongly suggest reciprocal modulation of the opioidergic and endocannabinoid systems, a relationship that has not been demonstrated in humans. This study sought to clarify this interaction by assessing how a range of naltrexone doses altered the subjective, cognitive, and cardiovascular effects of marijuana. Daily marijuana smokers (n = 29) participated in this...

Altered neurobehavioral reward response predicts psychotic-like experiences in youth exposed to cannabis prenatally

Carolyn M. Amir, Dara G. Ghahremani, Sarah E. Chang et al. preprint

Abstract Importance Rates of prenatal cannabis exposure (PCE) are rising with increasingly permissive legislation regarding cannabis use, which may be a risk factor for psychosis. Disrupted reward-related neural circuitry may underlie this relationship. Objective To elucidate neural mechanisms involved in the association between PCE and youth-onset psychotic-like experiences by probing...